Artificial Intelligence, Real-World Automation and the Safety of Medicines
- 7 October 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Drug Safety
- Vol. 44 (2), 125-132
- https://doi.org/10.1007/s40264-020-01001-7
Abstract
Despite huge technological advances in the capabilities to capture, store, link and analyse data electronically, there has been some but limited impact on routine pharmacovigilance. We discuss emerging research in the use of artificial intelligence, machine learning and automation across the pharmacovigilance lifecycle including pre-licensure. Reasons are provided on why adoption is challenging and we also provide a perspective on changes needed to accelerate adoption, and thereby improve patient safety. Last, we make clear that while technologies could be superimposed on existing pharmacovigilance processes for incremental improvements, these great societal advances in data and technology also provide us with a timely opportunity to reconsider everything we do in pharmacovigilance operations to maximise the benefit of these advances.Keywords
This publication has 70 references indexed in Scilit:
- Computational Phenotype Discovery Using Unsupervised Feature Learning over Noisy, Sparse, and Irregular Clinical DataPLOS ONE, 2013
- Terminological Challenges in Safety SurveillanceDrug Safety, 2012
- Reporting Patterns Indicative of Adverse Drug InteractionsDrug Safety, 2011
- Prescription Medicines and the Risk of Road Traffic Crashes: A French Registry-Based StudyPLoS Medicine, 2010
- A Decade of Data Mining and Still CountingDrug Safety, 2010
- Five Years After To Err Is HumanJAMA, 2005
- Perspectives on the Use of Data Mining in PharmacovigilanceDrug Safety, 2005
- CIOMS and ICH Initiatives in Pharmacovigilance and Risk ManagementDrug Safety, 2004
- The Medical Dictionary for Regulatory Activities (MedDRA)Drug Safety, 1999
- Comprehensive drug surveillanceJAMA, 1970